SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS

NEW YORK, Sept. 5, 2017

The investigation concerns whether Cellectis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On September 5, 2017, Cellectis announced the U.S. Food and Drug Administration's suspension of two early-stage studies for the Company's experimental blood cancer treatment UCART123, following the death of a patient. 

On this news, Cellectis's share price has fallen as much as $10.18, or 31.63%, during intraday trading on September 5, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, tecknown as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Wiloughby
Pomerantz LLP
rswilloughby@pomlaw.com